At the time of AML transformation, the most commonly detected mutation was in SRSF2 (47.6%), followed by TET2 (34.8%), ASXL1 (30.4%), IDH2 (26.1%), RUNX1 (21.7%), NRAS (21.7%), SETBP1 (19%), DNMT3A (17.4%), U2AF1 (14.3%), SF3B1 (14.3%), JAK2 (13%), CBL (13%), FLT3 (13%), ZRSR2 (9.5%), PHF6 (9.5%), and KRAS (8.7%). This evidence concerns the gene KRAS and acute myeloid leukemia.